BeyondSpring Inc. (BYSI)
D
Pipeline Grade
Financial Position (from SEC Filings)
$4.0M
Cash & Equivalents
$3.3M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$59M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-01 | Phase2 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05130827 | Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell T... | PHASE2 | Active Not Recruiting | 17 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-04 | 8-K | BeyondSpring Inc. (BYSI) (CIK 0001677940) - PRESS RELEASE | EDGAR |